Integra LifeSciences (IART) has enrolled its 100th patient in a prospective, multicenter observational registry evaluating the real-world clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients aged eight years or older, the company said Tuesday.

The AERA Pediatric Registry is designed to generate real-world evidence regarding the use of the system in children with obstructive Eustachian tube dysfunction, according to a statement.

Integra said it is targeting enrollment of 300 patients.

Price: 16.35, Change: +0.07, Percent Change: +0.46